appScorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Glenmark Pharmaceuticals Ltd
GLENMARK
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).
Brands
Investor PresentationView older
View Older PresentationsBrands
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Increased Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has increased by 1.94%
Recent NewsAll news
Glenmark Pharma Q2 Result Review- Muted Quarter; Divestment To Strengthen Financial Standing: ICICI Securities
2 weeks ago•Bloomberg Quint
Glenmark Pharma Q2 Review - Muted Show In India, U.S., Higher Interest Cost Drags Earnings: Motilal Oswal
2 weeks ago•Bloomberg Quint
Glenmark Pharma Shares Fall 5% After Q2 Loss, Estimates Miss
2 weeks ago•Bloomberg Quint
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant